newsfilter
← Latest News
Business Wire·

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Analyses of non-clinical study data demonstrate longer tumor retention with 177Lu-FAP-2286 than 177Lu-FAPI-46, resulting in greater tumor inhibition Phase 1 data is expected later this year from the ongoing LuMIERE clinical trial evaluating FAP-22